Genetics

In the ever-evolving landscape of multiple sclerosis care, understanding how patients respond to treatment is no longer just about visible relapses or MRI scans. This blog explores the game-changing role of blood neurofilament light chain (bNfL) testing—a minimally invasive biomarker that captures hidden nerve damage before symptoms even surface. Drawing from a 2025 expert consensus, we uncover how this blood test can help clinicians detect silent disease activity, personalize therapy plans, and intervene earlier, especially for patients who seem stable but may be quietly progressing.